Home | Business News | CBJ Newsmakers | Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors RecommendedChristina Lake Closes Second Tranche of Non-Brokered Private PlacementMount Logan Capital Inc. Announces Transaction with Canaccord Genuity G Ventures Corp. will not ProceedStallion Discoveries Announces $2 Million Non-Brokered Private Placement Financing
